$PHVS News

Last published 2d ago

2d agoPHVSGuggenheim 3rd Annual Healthcare Innovation Conference - PHARVARIS NVEarnings Call TranscriptsAnd thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I am Devjit, one of the therapeutic analysts. And joining me on stage are Pang Liu, president, and Maggie Beller, the head of IR from
1w agoPHVSPharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingGlobeNewswireZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1mo agoPHVSPhase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetGlobeNewswireResults from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR showed a
1mo agoPHVSPharvaris - Morgan Stanley 24th Annual Global Healthcare Conference - PHARVARIS NVEarnings Call TranscriptsGreat. Thank you very much, everyone, for attending. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at
1mo agoPHVSMorgan Stanley 24th Annual Global Healthcare Conference - PHARVARIS NVEarnings Call TranscriptsGreat. Thank you very much, everyone, for attending. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at
2mo agoPHVSPHARVARIS CHAPTER-3 TOPLINE DATA - PHARVARIS NVEarnings Call TranscriptsWelcome to the top-line data announcement of Chapter 3, a Phase 3 clinical study of Ducryptivant extended-release tablet for the prophylactic treatment of hereditary angioedema attacks. My name is Maggie Beller, Head of
2mo agoPHVSPharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE AttacksGlobeNewswirePrimary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in people with HAE
2mo agoPHVSPharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026GlobeNewswireZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with
3mo agoPHVSPharvaris Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTopline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA
3mo agoPHVSAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyGlobeNewswirePeople with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-beingStudy results informed the design and endpoint selection of the
3mo agoPHVSPublication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated AngioedemaGlobeNewswireProvides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2
4mo agoPHVSPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema AttacksGlobeNewswireIf approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to
4mo agoPHVSData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026GlobeNewswireResults from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentationEvidence on the cardiovascular safety
5mo agoPHVSPharvaris Announces Annual General Meeting of ShareholdersGlobeNewswireZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
5mo agoPHVSPharvaris to Present Clinical Data at the EAACI Annual Congress 2026GlobeNewswireZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
6mo agoPHVS2026 GLOBAL HEALTHCARE CONFERENCEPHARVARIS NVEarnings Call TranscriptsOkay. Good morning, everybody. Welcome back to the Bank of America Healthcare Conference. I'm Tazina Mudd. I'm one of the senior biotech analysts at the firm. It's my pleasure to have with us our next presenting company,
6mo agoPHVSPharvaris Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTopline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks
6mo agoPHVSPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs
6mo agoPHVSPharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary SharesGlobeNewswireZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs
6mo agoPHVSEvidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 ConferenceGlobeNewswireZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
7mo agoPHVSPharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant IR for on-demand
8mo agoPHVSDeucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026GlobeNewswireRAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and
9mo agoPHVSPharvaris to Present Clinical Data at the AAAAI 2026 Annual MeetingGlobeNewswireZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
10mo agoPHVSPharvaris Outlines 2026 Strategic PrioritiesGlobeNewswireTopline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing;
11mo agoPHVSPharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE AttacksGlobeNewswirePrimary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of
12mo agoPHVSPharvaris Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTopline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 study of
1y agoPHVSData Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific MeetingGlobeNewswireOpen-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentationsFinal
1y agoPHVSPharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific MeetingGlobeNewswireZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
1y agoPHVSPharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoPHVSPharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoPHVSPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTopline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for
1y agoPHVSPharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of
1y agoPHVSPharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of
1y agoPHVSPharvaris Announces Proposed Public Offering of Ordinary SharesGlobeNewswireZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of
1y agoPHVSPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitGlobeNewswireZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVS RCKTNodThera Announces Appointment of Elisabeth Björk as Board MemberGlobeNewswireNodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and
1y agoPHVSPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressGlobeNewswireZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Announces Annual Meeting of ShareholdersGlobeNewswireZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated AngioedemaGlobeNewswireDeucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential
1y agoPHVSPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming CongressesGlobeNewswireZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of
1y agoPHVSPharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4GlobeNewswireZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireTarget enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase
1y agoPHVSPharvaris Announces Orphan Designation Granted to Deucrictibant by the European CommissionGlobeNewswireZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint CongressGlobeNewswireReduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached
1y agoPHVSPharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025GlobeNewswireZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living
1y agoPHVSPharvaris Outlines 2025 Strategic PrioritiesGlobeNewswireInitiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026Enrollment in RAPIDe-3, the pivotal Phase 3 study of
1y agoPHVSPharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesGlobeNewswirePositive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congressesIntend to engage in clinical development of
1y agoPHVSPharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswireZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema